Distributes respiratory care equipment, including PAP devices and ventilators. Provides oxygen equipment and related replacement parts. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 57% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 21% of them.
No analyst target is on record for this company.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 57% a year on average.
Sales run at $27.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 25 buys and 6 sells. Management buying with its own money is usually read as a good sign.
A loss of $35.4M against $27.8M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 5/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 14/100. For a turnaround signal, the stock first needs to close the gap with the market.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.